Floatz logo

Rintatolimod

Mismatch Repair Proficient

Roswell Park Cancer InstitutePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Mismatch Repair Proficient cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Roswell Park Cancer Institute
Phase 2CCC
Epirubicin
Roswell Park Cancer Institute
Phase 2CCC
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2CCC

Same molecule, other indications

Rintatolimod is also rated in:

breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →
breast carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
estrogen-receptor negative breast cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →